Metabolic rewiring of pancreatic ductal adenocarcinoma: New routes to follow within the maze

International Journal of Cancer

Volumn 138, Issue 4, 2016, Pages 787-796

  Olivares, Orianne ^a,b,c,d   Vasseur, Sophie ^a,b,c,d  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c CNRS   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

metabolism; non essential amino acids; pancreatic cancer; proline

Indexed keywords

2 HYDROXY GLUTARATE; AMINO ACID; ARGININE; ENZYME; FUMARATE HYDRATASE; GLUCOSE; GLUCOSE TRANSPORTER; GLUTAMINE; ISOCITRATE DEHYDROGENASE; LACTATE TRANSPORTER; MATRIX METALLOPROTEINASE; NITRIC OXIDE; PHOSPHOGLYCERATE DEHYDROGENASE; PROLINE; REACTIVE OXYGEN METABOLITE; SUCCINATE DEHYDROGENASE; UNCLASSIFIED DRUG;

BIOMASS; BLOOD FLOW; CACHEXIA; CANCER ASSOCIATED FIBROBLAST; CANCER PATIENT; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME MODIFICATION; ENZYME SYNTHESIS; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GLYCOLYSIS; HUMAN; IN VITRO STUDY; MACROPHAGE; METABOLIC DISORDER; METABOLIC REWIRING; METABOLISM; METABOLITE; NUCLEAR REPROGRAMMING; ONCOGENE; ONCOGENE K RAS; ONCOGENE P16; OXIDATION REDUCTION STATE; PANCREAS ADENOCARCINOMA; PARAMETABOLISM; PINOCYTOSIS; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR SUPPRESSOR GENE; UREA CYCLE; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY;

CARCINOMA, PANCREATIC DUCTAL; HUMANS; PANCREATIC NEOPLASMS;

EID: 84954397459     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29501     Document Type: Review

References (90)

1. Siegel R, Naishadam D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Malvezzi M, Bertuccio P, Levi F, et al., European cancer mortality predictions for the year 2013. Ann Oncol 2013; 24: 792-800.
3. Bilimoria KY, Bentrem DJ, Ko CY, et al., Validation of the 6th edition AJCC pancreatic cancer staging system: report from the national cancer database. Cancer 2007; 110: 738-44.
4. Rochefort MM, Ankeny JS, Kadera BE, et al., Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system. Ann Surg Oncol 2013; 20: 4322-9.
5. Hezel AF, Kimmelman AC, Stanger BZ, et al., Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006; 20: 1218-49.
6. Han H, Von Hoff DD,. SnapShot: pancreatic cancer. Cancer Cell 2013; 23: 424.
7. Rooman I, Real FX,. Pancreatic ductal adenocarcinoma and acinar cells: a matter of differentiation and development? Gut 2012; 61: 449-58.
8. Armstrong T, Packham G, Murphy LB, et al., Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res 2004; 10: 7427-37.
9. Ohlund D, Lundin C, Ardnor B, et al., Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer. Br J Cancer 2009; 101: 91-7.
10. Willumsen N, Bager CL, Leeming DJ, et al., Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls. BMC Cancer 2013; 21: 13554.
11. Kang CY, Wang J, Axell-House D, et al., Clinical significance of serum COL6A3 in pancreatic ductal adenocarcinoma. J Gastrointest Surg 2014; 18: 7-15.
12. Koong AC, Mehta VK, Le QT, et al., Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000; 48: 919-22.
13. Guillaumond F, Leca J, Olivares O, et al., Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci USA 2013; 110: 3919-24.
14. Cowan RW, Maitra A,. Genetic progression of pancreatic cancer. Cancer J 2014; 20: 80-4.
15. Wang Z, Ali S, Banerjee S, et al., Activated K-ras and INK4a/arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. J Cell Physiol 2013; 228: 556-62.
16. Aguirre AJ, Bardeesy N, Sinha M, et al., Activated K-Ras and INK4a/arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003; 17: 3112-26.
17. Collins MA, Bednar F, Zhang Y, et al., Oncogenic K-Ras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 2012; 122: 639-53.
18. Bardeesy N, Aguirre AJ, Chu GC, et al., Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 2006; 103: 5947-52.
19. Kojima K, Vickers SM, Adsay NV, et al., Inactivation of Smad4 accelerates kras(G12D)-mediated pancreatic neoplasia. Cancer Res 2007; 67: 8121-30.
20. Bardeesy N, Cheng KH, Berger JH, et al., Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 2006; 20: 3130-46.
21. Bardeesy N, Morgan J, Sinha M, et al., Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. Mol Cell Biol 2002; 22: 635-43.
22. Morton JP, Timpson P, Karim SA, et al., Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 2010; 107: 246-51.
23. Samore WR, Gondi CS,. Brief overview of selected approaches in targeting pancreatic adenocarcinoma. Expert Opin Investig Drugs 2014; 23: 793-807.
24. Kroemer G, Pouyssegur J,. Tumour cell metabolism: cancer Achilles' heel. Cancer Cell 2008; 13: 473-82.
25. DeBernardinis RJ, Lum JJ, Hatzivassiliou G, et al., The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
26. Cairns RA, Harris IS, Mak TW,. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11: 85-95.
27. Ying H, Kimmelman AC, Lyssiotis CA, et al., Oncogenic K-Ras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012; 149: 656-70.
28. Vousden KH, Ryan KM,. p53 and metabolism. Nat Rev Cancer 2009; 9: 691-700.
29. De Souza AC, Justo GZ, de Araújo DR, et al., Defining the molecular basis of tumor metabolism: a continuing challenge since Warburg's discovery. Cell Physiol Biochem 2011; 28: 771-92.
30. Warburg O,. On the origin of cancer cells. Science 1956; 123: 309-14.
31. Vander Heiden MG, Cantley LC, Thomson CB,. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-33.
32. Semenza GL,. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 2010; 20: 51-6.
33. Ravi R, Mookerjee B, Bhujwalla ZM, et al., Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Gene Dev 2000; 14: 34-44.
34. Hirschhaeuser F, Sattler UG, Mueller-Klieser W,. Lactate: a metabolic key player in cancer. Cancer Res 2011; 71: 6921-5.
35. Frezza C, Gottlieb E,. Mitochondira in cancer: not just innocent bystanders. Semin Cancer Biol 2009; 19: 4-11.
36. Schell JC, Olson KA, Jiang L, et al., Role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth. Mol Cell 2014; 56: 400-13.
37. Pavlides S, Whitaker-Menezes D, Castello-Cros R, et al., The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009; 8: 3984-4001.
38. Bonuccelli G, Avnet S, Grisendi G, et al., Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells. Oncotarget 2014; 5: 7575-88.
39. Son J, Lyssiotis CA, Ying H, et al., Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013; 496: 101-5.
40. Wigmore SJ, Plester CE, Richardson RA, et al., Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 1997; 75: 106-9.
41. Bosaeus I, Daneryd P, Svanberg E, et al., Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patient. Int J Cancer 2001; 93: 380-383.
42. Tisdale MJ,. Mechanisms of cancer cachexia. Physiol Rev 2009; 89: 381-410.
43. Petruzzelli M, Schweiger M, Schreiber R, et al., A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab 2014; 20: 433-47.
44. Vissers YL, Dejong CH, Luiking YC, et al., Plasma arginine concentrations are reduced in cancer patients: evidence for arginine deficiency?. Am J Clin Nutr 2005; 81: 1142-6.
45. Yu KH, Barry CG, Austin D, et al., Stable isotope dilution multidimensional liquid chromatography-tandem mass spectrometry for pancreatic cancer serum biomarker discovery. J Proteome Res 2009; 8: 1565-76.
46. Menon R, Zhang Q, Zhang Y, et al., Identification of novel alternative splice isoforms of circulating proteins in a mouse model of human pancreatic cancer. Cancer Res 2009; 69: 300-9.
47. Bathe OF, Shaykhutdinov R, Kopciuk K, et al., Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol Biomarkers Prev 2011; 20: 140-7.
48. Ritchie SA, Akita H, Takemasa I, et al., Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer 2013; 13: 416.
49. Napoli C, Sperandio N, Lawlor RT, et al., Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution. J Proteome Res 2012; 11: 1274-83.
50. Wang F, Permert J,. Specific amino acid profile in culture media conditioned by human pancreatic cancer cell lines. Pancreatology 2002; 2: 402-6.
51. Oermann EK, Wu J, Guan KL, et al., Alterations of metabolic genes and metabolites in cancer. Semin Cell Dev Biol 2012; 23: 370-80.
52. Yang M, Soga T, Pollard PJ,. Oncometabolites: linking altered metabolism with cancer. J Clin Invest 2013; 123: 3652-8.
53. Dang L, White DW, Gross S, et al., Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-44.
54. Xu W, Yang H, Liu Y, et al., Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19: 17-30.
55. Dong X, Tang H, Hess KR, et al., Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer. Cancer 2011; 117: 480-91.
56. Christofk HR, Vander Heiden MG, Wu N, et al., Pyruvate KInase M2 is a phosphotyrosine-binding protein. Nature 2008; 452: 230-3.
57. Christofk HR, Vander Heiden MG, Harris MH, et al., The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 181-6.
58. Kumar Y, Gurusamy K, Pamecha V, et al., Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis. Pancreas 2007; 35: 114-9.
59. Zhao Y, Lee WN, Lim S, et al., Quantitative proteomics: measuring protein synthesis using 15N amino acid labeling in pancreatic cancer cells. Anal Chem 2009; 81: 764-71.
60. Xiao J, Lee WN, Zhao Y, et al., Profiling pancreatic cancer-secreted proteome using 15N amino acids and serum-free media. Pancreas 2010; 39: 17-23.
61. Yabushita S, Fukamachi K, Tanaka H, et al., Metabolomic and transcriptomic profiling of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas. Carcinogenesis 2013; 34: 1251-9.
62. Zhou W, Capello M, Fredolini C, et al., Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. J Proteome Res 2012; 11: 554-63.
63. Leichtle AB, Ceglarek U, Weinert P, et al., Pancreatic carcinoma, pancreatitis, and healthy controls: metabolite models in a three-class diagnostic dilemma. Metabolomics 2013; 9: 677-87.
64. Wu G, Bazer FW, Davis TA, et al., Arginine metabolism and nutrition in growth, health and disease. Amino Acids 2009; 37: 153-68.
65. Morris SM,. Arginine metabolism: boundaries of our knowledge. J Nutr 2007; 137: 1602-1609.
66. Gerner EW, Meyskens FL,. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004; 4: 781-92.
67. Meares GP, Hughes KJ, Jaimes KF, et al., AMP-activated protein kinase attenuates nitric oxide-induced β-cell death. J Biol Chem 2010; 285: 3191-200.
68. Lampson BL, Kendall SD, Ancrile BB, et al., Targeting eNOS in pancreatic cancer. Cancer Res 2012; 72: 4472-82.
69. Bowles TL, Kim R, Galante J, et al., Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer 2008; 123: 1950-5.
70. Huang CC, Tsai ST, Kuo CC, et al., Arginine deprivation as a new treatment strategy for head and neck cancer. Oral Oncol 2012; 48: 1227-35.
71. Buijs N, van Bokhorst-de van der Schueren MA, Langius JA, et al., Perioperative arginine-supplemented nutrition in malnourished patients with head and neck cancer improves long-term survival. Am J Clin Nutr 2010; 92: 1151-6.
72. Phang JM, Liu W, Hancock C,. Bridging epigenetics and metabolism: role of non-essential amino acids. Epigenetics 2013; 8: 231-6.
73. Phang JM, Liu W, Zabirnyk O,. Proline metabolism and microenvironmental stress. Annu Rev Nutr 2010; 30: 441-63.
74. Phang JM, Liu W, Hancock C, et al., The proline regulatory axis and cancer. Front Oncol 2012; 2: 60.
75. Liu W, Glunde K, Bhujwalla ZM, et al., Proline oxidase promotes tumor cell survival in hypoxic tumor microenvironments. Cancer Res 2012; 72: 3677-86.
76. Liu W, Le A, Hancock C, et al., Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci USA 2012; 109: 8983-8.
77. Possemato R, Marks KM, Shaul YD, et al., Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011; 476: 346-50.
78. Tedeschi PM, Markert EK, Gounder M, et al., Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell Death Dis 2013; 4: e877.
79. Kerr MC, Teasdale RD,. Defining macropinocytosis. Traffic 2009; 10: 364-371.
80. Commisso C, Davidson SM, Soydaner-Azeloglu RG, et al., Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 2013; 497: 633-7.
81. Chu GC, Kimmelman AC, Hezel AF, et al., Stromal biology of pancreatic cancer. J Cell Biochem 2007; 101: 887-907.
82. Sherman MH, Yu RT, Engle DD, et al., Vitamin d receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 2014; 159: 80-93.
83. Fukuda A, Wang SC, Morris JP, IV, et al., Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 2011; 19: 441-55.
84. Walter K, Omura N, Hong SM, et al., Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts. Clin Cancer Res 2010; 16: 1781-9.
85. Ijichi H, Chytil A, Gorska AE, et al., Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest 2011; 121: 4106-17.
86. Apte MV, Wilson JS,. Dangerous liaisons: pancreatic stellate cells and pancreatic cancer cells. J Gastroenterol Hepatol 2012; 27: 69-74.
87. Feig C, Gopinathan A, Neesse A, et al., The pancreas cancer microenvironment. Clin Cancer Res 2012; 18: 4266-76.
88. Ganji SK, Maher EA, Choi C,. In vivo 1 H MRSI of glycine in brain tumors at 3T. Magn Reson Med 2015; doi: 10.1002/mrm.25588.
89. Choi C, Ganji SK, DeBerardinis RJ, et al., 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012; 18: 624-9.
90. Choi C, Ganji SK, Madan A, et al., In vivo detection of citrate in brain tumors by 1H magnetic resonance spectroscopy at 3T. Magn Reson Med 2014; 72: 316-23.